N-(ortho-carboxyphenyl)retinamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: N-(ortho-carboxyphenyl)retinamide
• 英文别名: N-(2-carboxyphenyl)retinamide；2-[[(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoyl]amino]benzoic acid
• 化学式: C₂₇H₃₃NO₃
• 分子量: 419.564
• InChiKey: OAEICKHCODUZKG-FUQLHJDNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  维A酸 在 吡啶 、 六氯丙酮 、 triphenylphosphine-resin 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 N-(ortho-carboxyphenyl)retinamide
  参考文献：
  名称：

  Solid phase-assisted synthesis and screening of a small library of N-(4-hydroxyphenyl)retinamide (4-HPR) analogs

  摘要：

  Using solid phase-assisted synthesis and purification, a 49 member library of analogs of the main mammary tumor chemopreventive retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) has been prepared. After prescreening for growth inhibitory activity in human mammary tumor cells (MCF-7) in culture, most of those analogs which showed activity (12 of them) were assayed for apoptosis-inducing activity in the MCF-7 cells. At least 3 of the analogs (13, 24, and 28) showed activity approaching that of 4-HPR. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.050

文献信息

• Solid phase synthesis of arylretinamides
  申请人：——

  公开号：US20030105164A1

  公开（公告）日：2003-06-05

  A solid phase synthetic method for preparing arylretinamides is provided. The method comprises reacting hexachloroacetone with a solvent-suspended resin-bound triphenylphosphine to provide a suspension comprising an activated chlorinating reagent; reacting retinoic acid with the activated chlorinating reagent to provide retinoyl chloride; adding pyridine and a select arylamine to the resulting mixture; and stirring the resulting mixture for a time and at a temperature sufficient for the select arylamine to react with the retinoyl chloride and provide the arylretinamide. Also provided, are select arylretinamides that can be prepared by the present method, and methods of using such arylretinamides to induce apoptosis in cancer cells.

  提供了一种用于制备芳基维甲酰胺的固相合成方法。该方法包括将六氯乙酮与悬浮于溶剂中的树脂结合的三苯基膦反应，以提供含有活化氯化试剂的悬浮液；将维甲酸与活化氯化试剂反应以提供维甲酰氯；向得到的混合物中加入吡啶和选择的芳基胺；并在足够时间和温度下搅拌得到的混合物，以使选择的芳基胺与维甲酰氯反应并提供芳基维甲酰胺。还提供了可以通过该方法制备的选择性芳基维甲酰胺，以及使用这些芳基维甲酰胺在癌细胞中诱导凋亡的方法。
• Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
  申请人：Scaramuzzino, Giovanni

  公开号：EP1336602A1

  公开（公告）日：2003-08-20

  New pharmaceutical compounds of general formula (I): F-(X)q where q is an integer from 1 to 5, preferably 1; -F is chosen among drugs described in the text, -X is chosen among 4 groups -M, -T, -V and -Y as described in the text. The compounds of general formula (I) are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

  通式（I）的新药物化合物：F-（X）q，其中q是1到5的整数，最好是1；-F是在文本中描述的药物中选择的，-X是在文本中描述的4个组-M，-T，-V和-Y中选择的。通式（I）的化合物是硝酸盐前药，可以在体内以受控和选择性的方式释放一氧化氮，而不会产生降压副作用，因此它们非常适用于制备用于预防和治疗肌肉骨骼，皮肤，呼吸，消化，泌尿和中枢神经系统的炎症，缺血，退行性和增生性疾病的药物。
• COMPOUNDS AND THERAPEUTICAL USE THEREOF
  申请人：Cai Xiong Sui

  公开号：US20070244114A1

  公开（公告）日：2007-10-18

  Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明揭示了4-芳氨基喹唑啉及其类似物，其作为caspase激活剂和诱导凋亡剂具有有效性。本发明的化合物在治疗各种临床病症中具有用途，这些病症中存在异常细胞的不受控制的生长和扩散。
• Mitotic kinesin inhibitors
  申请人：Arrington L Kenneth

  公开号：US20060063942A1

  公开（公告）日：2006-03-23

  The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

  本发明涉及二氢吡唑化合物，其可用于治疗细胞增殖性疾病，治疗与KSP肌动蛋白活性相关的疾病，并抑制KSP肌动蛋白。本发明还涉及包含这些化合物的组合物，以及使用它们治疗哺乳动物癌症的方法。
• Retinsäure- und 7,8-Dehydro-retinsäure-N-(carboxy)-phenyl-amide, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
  申请人：BASF Aktiengesellschaft

  公开号：EP0009777A1

  公开（公告）日：1980-04-16

  Die Erfindung betrifft all-E- und 13-Z-Retinsäure- Verbindungen der Formel I und II, in denen die gestrichelte Linie eine chemische Bindung oder zwei Wasserstoffatome darstellt und die Carboxylgruppe am aromatischen Ring in ortho-, meta- oder p-Position stehen kann, die Herstellung dieser Verbindungen, diese Verbindungen enthaltende pharmazeutische Zubereitungen und ihre Verwendung als Arzneimittel bei der topischen und systemischen Therapie und Prophylaxe von Praekanzerosen und Karzinomen und von dermatologischen Erkrankungen.

  本发明涉及式 I 和 II 的全-E-和 13-Z-维甲酸化合物，其中 虚线代表一个化学键或两个氢原子，芳香环上的羧基可以位于正位、偏位或 p 位；本发明涉及这些化合物的制备方法、含有这些化合物的药物组合物以及它们在局部和全身治疗和预防癌前病变、癌和皮肤病中的药物用途。